Clinical Trial Search

Primary: Percentage Of Participants With Delayed Graft Function (DGF) In The First Seven Days Post-transplant — 35.9; 41.7; 33.8; 39.6 percentage of participants — p=0.3983

Primary: Delayed Kidney Graft Function — 5; 7 Participants

Primary: Creatinine Clearance (CrCl) in the Immediate Post-transplant Period — 5.11; 7.44; 6.30; 9.66 mL/min — p=0.9076

Primary: Number of Days Needed to Recover From Delayed Graft Function (DGF) — 14.0; 15.0 days

Primary: Incidence of Poor Graft Function After Kidney Transplant — 13; 22 Participants

Primary: Number of Patients Enrolled With Serum Creatinine >3mg/dL on Postoperative Day 5. — 29; 32 Participants

Primary: Estimated Glomerular Filtration Rate (eGFR) at 12 Months Post-surgery — 72; 87.8; 51.0 mL/min

Primary: Proportion of Safety Events — 1 Participants

Primary: Number of Participants With Delayed Graft Function (DGF) — 12; 15 Participants

Primary: Need for Dialysis in the First 30 Days Post-transplant — 10; 10 Participants

Primary: Number of Participants With Progression of Renal Graft Fibrosis (Primary Comparison - ITT Population — 26; 31; 12; 16 Participants

Primary: Cytokines Evaluation — 380; 893; 763; 147 MFI — p=<0.05

Primary: Plasma Creatine Concentration of the Recipients — 849.5; 878.5; 771.0; 776.5 μmol/l

Primary: Compare Efficacy and Safety of Two Vitamin D Supplements of These Doses in Normalizing Vitamin D Concentrations. — 8; 29 ng/ml

Primary: The Difference Between the Mean eGFR (Modified MDRD) in the Experimental vs. Control Groups. — 52.45; 57.35 mL/min/1.73m2 — p=0.099

Primary: Early Allograft Dysfunction — 6; 18 Participants

Primary: BPAR (Biopsy-proven Acute Rejection) Incidence During the First 12 Months Post-transplant — 1; 3 participants — p=0.32

Primary: Calculated Estimated Glomerular Filtration Rate (eGFR) — 67.39; 80.48 ml/min/1.73m2 — p=0.32

Primary: Glomerular Filtration Rate at Baseline — 56; 67 mL/mnt/1.73 m^2

Primary: Renal Function — .46; .75; 4.26; 2.80 mL/min/1.73m^2 — p=>0.05

Primary: Myocardial Perfusion Reserve — 1.52; 1.94 arbitrary units

Primary: Percentage of Participants Who Were Positive for de Novo DSA (dnDSA) or Immune Activation (IA) Occurrence — 35.6; 34.4 percentage of participants — p=0.5777

Primary: Overall Recipient Survival at 6-month Post-relapse of Disease — 0; 4 participants

Primary: EAD — 1.23; 2.19; 0.87; 1.54 L/kg/min

Primary: Feasibility- Eligibility for Randomization — 54 Participants

Primary: Number of Participants Considered in Failure for the Primary Failure Endpoint at 3 Months — 36; 47; 16; 18 Participants

Primary: Percentage of Patients With Grade II-IV Acute GvHD by Day +100 Following Transplant — 94.4 percentage of participants

Primary: The Number of Patients With Relapse-free/Donor Lymphocyte Infusion(DLI)-Free Survival Rates Between Patients Randomized to MMF-30 (Control Cohort) and MMF-15…

Primary: Time to First Therapeutic Tacrolimus Trough Concentration From Initiation of Tacrolimus Extended Release Measured in Days — 4.5; 6; 13.5 days

Primary: Delayed Graft Function — 8; 12 participants